WO2004043474A2 - Verwendung eines oder mehrerer der elemente aus der gruppe yttrium, neodym und zirconium - Google Patents
Verwendung eines oder mehrerer der elemente aus der gruppe yttrium, neodym und zirconium Download PDFInfo
- Publication number
- WO2004043474A2 WO2004043474A2 PCT/EP2003/012532 EP0312532W WO2004043474A2 WO 2004043474 A2 WO2004043474 A2 WO 2004043474A2 EP 0312532 W EP0312532 W EP 0312532W WO 2004043474 A2 WO2004043474 A2 WO 2004043474A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- zirconium
- yttrium
- neodymium
- formulation according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/9155—Adjacent bands being connected to each other
Definitions
- compositions containing these elements Use of one or more of the elements from the group of yttrium, neodymium and zirconium, pharmaceutical compositions containing these elements
- the invention relates to the medical use of one or more of the elements from the group of yttrium, neodymium and zirconium, pharmaceutical formulations which contain these elements, and implants which are at least partially constructed from these formulations.
- Inflammation is understood to mean the reaction of the organism to an external or internal inflammation stimulus carried by the connective tissue and the blood vessels with the purpose of eliminating or inactivating this and to repair the irritation-related tissue damage.
- Mechanical stimuli foreign bodies, pressure, injury
- other physical factors ionizing rays, UV light, heat, cold
- chemical substances alkalis, acids, heavy metals, bacterial toxins, allergens and immune complexes
- pathogens microorganisms, worms
- Insects or pathological metabolic products (derailed enzymes, malignant tumors).
- the microbiological processes that are complex due to the aforementioned triggering factors usually go with the release of so-called growth factors such as FGF, PDGF and EGF that stimulate proliferation, that is, the proliferation of tissue through proliferation or sprouting.
- proliferation should be at least temporarily inhibited.
- mitotic poisons for example, to use mitotic poisons, ionizing rays or interferons to combat viruses.
- Coronary artery disease especially acute myocardial infarction
- myocardial infarction is one of the most common causes of death in Western Europe and North America.
- the cause of myocardial infarction is the thrombotic occlusion of a coronary artery due to rupture of atheromatous plaque in the presence of stenosing atheromatosis.
- Decisive factors for the long-term prognosis after acute myocardial infarction are:
- Non-surgical methods of stenosis treatment have been established for more than twenty years, in which the narrowed or closed blood vessel is widened again by balloon dilatation (PTCA percutaneous transluminal coronary angioplasty). This procedure has proven itself particularly in the treatment of acute myocardial infarction. With the widening of the blood vessel, however, the smallest injuries, tears, and dissections in the wall of the vessel occur, which often heal easily, but lead to proliferation in about a third of the cases through the triggered cell growth (proliferation ration), which ultimately lead to renewed vasoconstriction (restenosis). The widening also does not remove the causes of the stenosis, i.e. the molecular pathological changes in the vascular wall.
- Another cause of restenosis is the elasticity of the stretched blood vessel. After removing the balloon, the blood vessel contracts excessively, so that the cross-section of the vessel is reduced (obstruction, so-called negative remodeling). The latter effect can only be avoided by placing a stent.
- An optimal vascular cross-section can be achieved through the use of stents, but the use of stents also leads to the smallest injuries which can induce proliferation and thus ultimately trigger restenosis. Furthermore, the presence of such a foreign body initiates a cascade of cellular molecular processes that can lead to a gradual overgrowth of the stent.
- restenosis occurs as a reaction of the vascular wall to the local injury due to the stretching of the atherosclerotic plaque.
- the lumen-oriented migration and proliferation of the smooth muscle cells of the media and the adventitia is induced by complex mechanisms of action (neointimal hyperplasia).
- the smooth muscle cells produce a covering layer of neointimal smooth muscle cells and matrix proteins (elastin, collagen, proteoglycans), the uncontrolled growth of which can gradually lead to narrowing of the lumen.
- Systemic drug therapy uses include the oral administration of calcium antagonists, ACE inhibitors, anticoagulants, antiaggregants, fish oils, antiproliferative substances, anti-inflammatory substances and serotonin antagonists, however, significant reductions in the types of restenosis have not yet been achieved in this way.
- a possible explanation for the disappointing results of all previous attempts at systemic application of a wide variety of substances can be seen in the fact that systemic application cannot bring the substance in sufficient concentration to the site of the vascular injury.
- LDD local drug delivery
- the support of such coating systems consists of a biocompatible material, which is either of natural origin or can be obtained by synthetic means.
- Biodegradable coating materials offer particularly good tolerability and the possibility of influencing the elution characteristics of the embedded drug.
- examples of the use of biodegradable polymers are cellulose, collagen, albumin, casein, polysaccharides (PSAC), polylactide (PLA), poly-L-lactide (PLLA), polyglycol (PGA), poly-D, L-lactide-co-glycolide (PDLLA / PGA), polyhydroxybutyric acid (PHB), polyhydroxyvaleric acid (PHV), polyalkylcarbonates, polyorthoesters, polyethylene terephthalate (PET), polymalonic acid (PML), polyanhydrides, polyphosphazenes, polyamino acids and their copolymers as well as hyaluronic acid and its derivatives.
- PSAC polysaccharides
- PLA polylactide
- stents made from medical steel (316L).
- biodegradation is understood to mean hydrolytic, enzymatic and other metabolic degradation processes in the living organism that lead to an gradual dissolution of at least large parts of the implant.
- biocorrosion is often used synonymously.
- bioresorption also includes the subsequent absorption of the degradation products.
- stent materials which, although exhibiting good degradation behavior, are only of limited use for medical applications due to their mechanical properties and - at least in the case of synthetic polymers based on PU and LDA derivatives - also cause a strong inflammatory reaction and stimulate neointima proliferation.
- the metal alloys include special biodegradable iron, tungsten and magnesium alloys.
- a stent is known from US Pat. No. 6,264,595. can contain radioactive yttrium isotopes, the radiation released when the isotopes decay should prevent restenosis after stent implantation.
- No. 4,610,241 describes a method for the treatment of atherosclerosis with ferro-, dia- or paramagnetic particles, which are heated up by alternating electromagnetic fields after being brought to the site of the lesion. The particles are said to include certain yttrium salts.
- Zirconium is part of numerous ceramic biomaterials. Previous in vivo and in vitro studies on special zirconium-containing ceramics provide no evidence of a pharmacological effect in connection with smooth human muscle cells (Piconi, C, Maccauro G., (1999) Biomaterials 20, 1-25).
- the present invention is inter alia the object of the invention is to provide the proliferation of human smooth muscle cell inhibitors and pharmaceutical formulations which are particularly suitable for use in endovascular implants such as stents.
- the object is achieved by using one or more of the elements from the group yttrium (Y), neodymium (Nd), or zirconium (Zr) for the preparation of a pharmaceutical formulation which inhibits the proliferation of human smooth muscle cells.
- Y yttrium
- Nd neodymium
- Zr zirconium
- Inhibiting cell growth over a certain period of time until the factors that stimulate growth are largely or completely eliminated can therefore effectively prevent restenosis.
- the elements yttrium, neodymium and / or zirconium are therefore particularly suitable for restenosis prophylaxis after stent implantation.
- the reasons for the surprising pharmaceutical effect of the elements yttrium, zirconium and / or neodymium on human arterial smooth muscle cells have not yet been completely clarified.
- the redox processes taking place in the cell medium with the participation of the metals presumably play an important role.
- Tetrahymena shanghaiensis Wang, Y., Zhang, M., and Wang, X. (2000) Biol Trace Elem Res 75 (1-3), 265-275
- Klebsieila pneumoniae strain 204 and K9 Aleksakhina, NN, Miriasova, LV, and Basnak'ian, IA (2002) Zh Mikrobiol Epidemiol Immunobiol (6), 13-18
- Pseudomonas fluorescens Appanna, VD, Hamel, RD, Pankar, E., and Méutereux-Dao, S. ( 2001) Microbios 106 (413), 19-29).
- a second aspect of the invention relates to pharmaceutical formulations which contain one or more of the elements from the group of yttrium, neodymium or zirconium.
- An advantageous adaptation of the pharmaceutical formulation is that the formulation comprises an at least largely biodegradable carrier which is broken down in vivo with a predetermined degradation behavior.
- degradation behavior is understood to mean the degradation of the carrier in the living organism that takes place over time through chemical, thermal, oxidative, mechanical or biological processes.
- This aspect of the invention is particularly important when the formulation for intravascular release after implantation in a vascular vessel has to be adapted, in particular the active ingredients should be applied locally in the area of the lesion to be treated, such approaches can be summarized under the term 'local drug delivery' (LDD).
- LDD local drug delivery'
- the biodegradable carrier is an alloy, in particular a magnesium, iron or tungsten alloy.
- a magnesium, iron or tungsten alloy Such metal alloys are known for example from DE 197 31 021 and DE 199 45 049.
- Another particularly suitable formulation based on a magnesium alloy has the following composition:
- the formulation preferably further comprises a magnesium alloy with a yttrium content in the range from 3.7 to 5.5% by weight, a content of neodymium in the range from 1.8 to 2.7% by weight and a content of zirconium in the range from 0.2 to 1.2% by weight.
- the formulation particularly preferably corresponds to the commercially available magnesium alloy WE43 (W-25 EP 5M).
- the carrier is a biodegradable polymer and one or more of the elements from the group of yttrium, neodymium or zirconium is embedded in the polymer in the form of powders or microparticles. Due to the gradual degradation of the polymer in vivo, the powder or the microparticles are slowly released and can develop their pharmacological effect after bioresorption.
- the polymeric carrier can in particular be hyaluronic acid, poly-L-lactide or a derivative of the polymers.
- the formulation yttrium in a proportion of 0.1 to 10% by weight, neodymium in a proportion of 0.1 to 5% by weight and / or zirconium in a proportion of 0.1 to 3% by weight , each based on the total weight of the formulation.
- the formulation according to the invention if it contains yttrium, is therefore adapted such that an yttrium concentration in the region of the human smooth muscle cells to be treated is between 200 ⁇ M to 2 mM, in particular between 800 to 1 mM. If the composition contains neodymium, the formulation is preferably adapted such that a neodymium concentration in the region of the human smooth muscle cells to be treated is between 600 ⁇ M to 2 mM, in particular between 800 ⁇ M to 1 mM.
- a zirconium concentration in the region of the human smooth muscle cells to be treated is preferably to be specified by specifically adapting the formulation between 200 ⁇ M to 2 mM, in particular between 200 ⁇ M to 1 mM.
- a formulation which contains yttrium, neodymium and zirconium it is particularly preferred to adapt the formulation in such a way that an yttrium concentration at 350 to 550 ⁇ M, a neodymium concentration at 100 to 200 ⁇ M and a zirconium concentration at 10 to 30 ⁇ M in the range of those to be treated human smooth muscle cells.
- the concentration ranges mentioned appear particularly suitable for restenosis prophylaxis Stent implantation, since the systemic substance delivery is very low and therefore at most a low systemic toxicity must be expected.
- the actual concentrations in the living organism depend on the degradation behavior of the formulation, which in turn depends on the specific composition of the formulation, and the diffusion behavior of the degradation products in the tissue. Theoretical predictions are difficult to make here and corresponding measurements are often associated with large measurement errors. In order for the aforementioned concentration ranges to occur in the vicinity of the human smooth muscle cells to be treated, experimental studies on the bioresorption of the selected formulation are generally still necessary.
- the coronary stents used there had a weight of 3 mg and contained 123 ⁇ g yttrium (4.1% by weight), 66 ⁇ g neodymium (2.2% by weight) and 15 ⁇ g zirconium (0.5% by weight).
- a third aspect of the invention relates to implants which have an at least partial coating from the above-mentioned formulation according to the invention or which consist structurally in parts of this formulation.
- Such an implant can preferably be designed as an endovascular support structure (stent).
- a distribution and mass of the formulation in a stent is preferably specified in relation to the length of the stent in such a way that approximately 5 to 30 ⁇ g / mm, in particular 10 to 20 ⁇ g / mm, yttrium are present.
- this requirement is preferably set to approximately 2 to 20 ⁇ g / mm, in particular 3 to 10 ⁇ g / mm, and for zirconium preferably to approximately 0.05 to 10 ⁇ g / mm, in particular 0.5 to 6 ⁇ g / mm, established.
- the range limits mentioned allow pharmacodynamically favorable local application of the active ingredients.
- a fourth aspect of the invention relates to the already known elements or combinations of elements from the group of yttrium, neodymium or zirconium, to which no therapeutic effect has yet been assigned, as therapeutic agents.
- this aspect relates to alloys which contain one or more elements from the group yttrium, neo- contain dym or zirconium.
- none of the elements / alloys have been assigned a therapeutic effect.
- 1 shows a table to illustrate the dependence of the vitality of arterial human smooth muscle cells on the concentration of yttrium, neodymium or zirconium after three days,
- FIG. 2 shows a further table to illustrate the dependence of the proliferation of smooth human muscle cells on the concentration of yttrium, neodymium or zirconium after three days.
- FIG. 3 shows a schematic representation of an endoprosthesis in the form of a stent
- FIG. 4 shows a typical section through a main coronary vessel of the pig after implantation of a conventional stent
- FIG 5 shows a typical section through a main coronary vessel of the pig after implantation of a stent made of the material WE43.
- yttrium chloride YClaV zirconium chloride (ZrCU, and neodvmium chloride (NdCl 3 ) in cell culture
- FIGS. 1 and 2 are based on test series on arterial human smooth muscle cells with a concentration in the range from 1 mM to 1 ⁇ M, in each case for yttrium, neodymium and zirconium. The tests were carried out as follows:
- the substances were dissolved in water or ethanol (ZrCI) (stock solution 0.1 M, in each case based on the concentration of the rare earths). When diluted in cell culture medium, precipitates formed at higher concentrations, which could be reduced by ultrasound treatment, but could not be completely eliminated.
- the eluates produced were incubated with primary cell cultures of human arterial smooth muscle cells (SMC) (3 days, 37 ° C.). Cell vitality (MTS test) and cell proliferation (BrdU test) were examined. For this purpose, tests were carried out analogously to a cytotoxicity test according to DIN EN 30993-5. The results of these tests are summarized in Tables 1 (vitality) and Table 2 (proliferation).
- the vitality of arterial human smooth muscle cells increased in the concentration range from 1 ⁇ M to 100 ⁇ M. Concentrations of> 800 ⁇ M neodymium and zirconium led to a decrease in vitality.
- the proliferation of arterial human smooth muscle cells was increasingly strongly inhibited at neodymium concentrations> 800 ⁇ M. Proliferation was already largely inhibited at yttrium concentrations of> 800 ⁇ M. At zirconium concentrations of 200 ⁇ M to 1 mM, the proliferation was on average 44%. Thus, yttrium and neodymium showed a strong effect on the proliferation of smooth muscle cells at higher concentrations. Zirconium had a moderate antiproliferative effect.
- Sterilized test specimens of alloy WE 43 with a weight of approx. 1 mg were eluted with 2 ml cell culture medium at 37 ° C in a cell culture cabinet for 13 days, the test specimen only going into solution incompletely.
- Primary cell cultures of human arterial smooth muscle cells (SMC) were then incubated with 1 ml of the eluate and 1 ml of fresh cell culture medium (4 days, 37 ° C.).
- Cell vitality (MTS test) and cell proliferation (BrdU test) were examined.
- tests were carried out analogously to a cytotoxicity test according to DIN EN 30993-5.
- the proliferation of smooth muscle cells was inhibited by 91% when incubated with eluates of alloy WE43 compared to control cells (SMC + medium).
- the cell vitality of the smooth muscle cells for the alloy WE43 was 95%.
- FIG. 3 shows a vascular endoprosthesis in the form of a tubular stent 10, the basic structure of which is composed of a large number of individual webs 12.
- the basic structure of the stent 10 can be divided in the longitudinal direction into individual support sections 14, which are each composed of a web 12 folded in a zigzag or meandering shape and extending in the circumferential direction.
- the basic structure of the stent 10 is formed by a plurality of such support sections 14 which follow one another in the longitudinal direction.
- the support sections 14 are connected to one another via connecting webs 16.
- two connecting webs 16 adjoining one another in the circumferential direction and the sub-sections of the support sections 14 lying opposite one another between these connecting webs 16 define a mesh 18 of the stent 10.
- Such a mesh 18 is shown highlighted in FIG.
- Each mesh 18 encloses a radial opening of the peripheral wall or the basic structure of the stent 10.
- Each support section 14 has approximately three to six connecting webs 16 which are equally distributed over the circumference of the stent 10 and which each connect a support section 14 to the adjacent support section 14. Accordingly, the stent 10 has three to six stitches in each case in the circumferential direction between two support sections 14.
- the stent 10 is expandable in the circumferential direction. This is done, for example, with a balloon catheter known per se and not shown here, which has a balloon expandable by means of a fluid at its distal end.
- the stent 10 is crimped onto the deflated balloon in the compressed state. As the balloon expands, both the balloon and the stent 10 are expanded. The balloon can then be deflated again and the stent 10 detaches from the balloon. In this way, the catheter can simultaneously serve to insert the stent 10 into a blood vessel and in particular into a constricted coronary artery and to expand the stent at this location.
- the basic structure of the stent 10 shown in FIG. 3 consists of the biodegradable magnesium alloy WE43 with the following formulation:
- Neodymium 2.2% by weight
- Magnesium balance to 100% by weight.
- stents made of the aforementioned magnesium alloy were compared with conventional silicon carbide-coated stents by means of coronary angiography and morphometric evaluation of histological sections.
- Conventional medical stainless steel stents with a passive silicon carbide coating and WE43 stents were implanted in all three pig coronaries.
- a quantitative control angiography (QCA) was performed after four and eight weeks, whereby the degradation of the biodegradable stent in the pig was largely completed after about 8 weeks. After 8 weeks, heart preparations for the animals were also prepared for histological processing.
- FIG. 4 shows a typical section through a coronary vessel of a pig after implantation of a conventional stent with a silicon carbide coating after eight weeks
- FIG. 5 shows a corresponding histological section for an implant based on WE43.
- neointima formation which can be estimated after eight weeks due to the morphometric cross-section of the neointima surfaces, is reduced by a factor of 2 when using WE43.
- the effect appears to be essentially due to the residues released during the degradation of the stent into the tissue environment, which in turn contain yttrium, neodymium and zirconium.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Surgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Prostheses (AREA)
- Polishing Bodies And Polishing Tools (AREA)
- Pens And Brushes (AREA)
- Compositions Of Oxide Ceramics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Carbon And Carbon Compounds (AREA)
- Catalysts (AREA)
- Luminescent Compositions (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/535,084 US20060246107A1 (en) | 2002-11-13 | 2003-10-11 | Use of one or more elements from the group containing yttrium, neodymium and zirconium and pharmaceutical compositions containing said elements |
AU2003288029A AU2003288029A1 (en) | 2002-11-13 | 2003-11-10 | Use of one or more elements from the group containing yttrium, neodymium and zirconium |
DE50309382T DE50309382D1 (de) | 2002-11-13 | 2003-11-10 | Verwendung eines oder mehrerer der elemente aus der gruppe yttrium, neodym und zirconium |
EP03779881A EP1562565B1 (de) | 2002-11-13 | 2003-11-10 | Verwendung eines oder mehrerer der elemente aus der gruppe yttrium, neodym und zirconium |
US12/575,596 US20100034899A1 (en) | 2002-11-13 | 2009-10-08 | Use of one or more of the elements from the group yttrium, neodymium and zirconium, and pharmaceutical compositions which contain those elements |
US12/575,613 US20100119576A1 (en) | 2002-11-13 | 2009-10-08 | Use of one or more of the elements from the group yttrium, neodymium and zirconium, and pharmaceutical compositions which contain those elements |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10253634.1 | 2002-11-13 | ||
DE10253634A DE10253634A1 (de) | 2002-11-13 | 2002-11-13 | Endoprothese |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/575,596 Division US20100034899A1 (en) | 2002-11-13 | 2009-10-08 | Use of one or more of the elements from the group yttrium, neodymium and zirconium, and pharmaceutical compositions which contain those elements |
US12/575,613 Division US20100119576A1 (en) | 2002-11-13 | 2009-10-08 | Use of one or more of the elements from the group yttrium, neodymium and zirconium, and pharmaceutical compositions which contain those elements |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004043474A2 true WO2004043474A2 (de) | 2004-05-27 |
WO2004043474A3 WO2004043474A3 (de) | 2005-01-13 |
Family
ID=32115564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/012532 WO2004043474A2 (de) | 2002-11-13 | 2003-11-10 | Verwendung eines oder mehrerer der elemente aus der gruppe yttrium, neodym und zirconium |
Country Status (7)
Country | Link |
---|---|
US (4) | US20060246107A1 (de) |
EP (2) | EP1419793B1 (de) |
JP (1) | JP5073913B2 (de) |
AT (2) | ATE316390T1 (de) |
AU (1) | AU2003288029A1 (de) |
DE (3) | DE10253634A1 (de) |
WO (1) | WO2004043474A2 (de) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005065737A1 (de) * | 2003-12-24 | 2005-07-21 | Biotronik Vi Patent Ag | Radioopaker marker für medizinische implantate |
DE10361941A1 (de) * | 2003-12-24 | 2005-07-28 | Restate Patent Ag | Magnesiumhaltige Beschichtung |
DE102004043232A1 (de) * | 2004-09-07 | 2006-03-09 | Biotronik Vi Patent Ag | Endoprothese aus einer Magnesiumlegierung |
DE102004043231A1 (de) * | 2004-09-07 | 2006-03-09 | Biotronik Vi Patent Ag | Endoprothese aus einer Magnesiumlegierung |
EP1642551A1 (de) * | 2004-09-09 | 2006-04-05 | Biotronik VI Patent AG | Implantat mit geringer Radialfestigkeit |
DE102005003188A1 (de) * | 2005-01-20 | 2006-07-27 | Restate Patent Ag | Medizinisches Implantat aus einer amorphen oder nanokristallinen Legierung |
WO2007035791A3 (en) * | 2005-09-19 | 2007-05-10 | Cook Inc | Graft with bioabsorbable support frame |
DE102006038233A1 (de) * | 2006-08-07 | 2008-02-14 | Biotronik Vi Patent Ag | Markerkomposit für medizinische Implantate |
EP2000551A1 (de) | 2007-05-28 | 2008-12-10 | Acrostak Corp. BVI | Magnesiumbasierte Legierungen |
DE102012018816A1 (de) | 2012-09-25 | 2014-03-27 | Mdi Dental- Und Implantattechnik Gmbh | Pharmazeutische Beschichtung für Aufbauten von Zahnimplantaten |
US9468704B2 (en) | 2004-09-07 | 2016-10-18 | Biotronik Vi Patent Ag | Implant made of a biodegradable magnesium alloy |
US10016530B2 (en) | 2008-09-30 | 2018-07-10 | Biotronik Ag | Implant made of a biodegradable magnesium alloy |
Families Citing this family (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6306166B1 (en) * | 1997-08-13 | 2001-10-23 | Scimed Life Systems, Inc. | Loading and release of water-insoluble drugs |
US20050267560A1 (en) * | 2000-02-03 | 2005-12-01 | Cook Incorporated | Implantable bioabsorbable valve support frame |
WO2003002243A2 (en) | 2001-06-27 | 2003-01-09 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
US7842083B2 (en) | 2001-08-20 | 2010-11-30 | Innovational Holdings, Llc. | Expandable medical device with improved spatial distribution |
DE10253634A1 (de) * | 2002-11-13 | 2004-05-27 | Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin | Endoprothese |
CA2527975C (en) * | 2003-06-13 | 2011-08-09 | Mnemoscience Gmbh | Biodegradable stents comprising a shape memory polymeric material |
DE102004029611A1 (de) * | 2004-02-06 | 2005-08-25 | Restate Patent Ag | Implantat zur Freisetzung eines Wirkstoffs in ein von einem Körpermedium durchströmtes Gefäß |
EP1711213B1 (de) * | 2004-02-06 | 2014-11-19 | Biotronik VI Patent AG | Implantat zur freisetzung eines wirkstoffs in ein von einem körpermedium durchströmtes gefäss |
DE102004026104A1 (de) * | 2004-05-25 | 2005-12-15 | Restate Patent Ag | Implantat zur Gefäßligatur |
DE102004035904A1 (de) * | 2004-07-20 | 2006-02-16 | Biotronik Vi Patent Ag | Implantierbare Elektrode |
EP1618919B1 (de) * | 2004-07-20 | 2012-07-04 | Biotronik CRM Patent AG | Fixierung für implantierbare Elektroden und Katheter |
DE102004036399A1 (de) * | 2004-07-23 | 2006-02-16 | Biotronik Vi Patent Ag | Biokompatibles und bioabsorbierbares Naht- und Klammermaterial für chirurgische Zwecke |
DE502005008226D1 (de) | 2004-09-07 | 2009-11-12 | Biotronik Vi Patent Ag | Endoprothese aus einer Magnesiumlegierung |
JP2006167078A (ja) * | 2004-12-15 | 2006-06-29 | Terumo Corp | 医療用インプラント |
US8293261B2 (en) * | 2005-01-28 | 2012-10-23 | Terumo Kabushiki Kaisha | Intravascular implant |
US20060198869A1 (en) * | 2005-03-03 | 2006-09-07 | Icon Medical Corp. | Bioabsorable medical devices |
DE102005013221A1 (de) * | 2005-03-17 | 2006-09-21 | Biotronik Vi Patent Ag | System zur Behandlung ausgedehnter obliterierender Erkrankungen eines Gefäßes |
DE102005018356B4 (de) * | 2005-04-20 | 2010-02-25 | Eurocor Gmbh | Resorbierbare Implantate |
US20070010896A1 (en) * | 2005-05-19 | 2007-01-11 | Biophan Technologies, Inc. | Electromagnetic resonant circuit sleeve for implantable medical device |
DE102005031361A1 (de) | 2005-06-30 | 2007-01-04 | Biotronik Vi Patent Ag | Verwendung von Propolis als Beschichtungsmaterial für medizinische Implantate |
DE102005031868A1 (de) * | 2005-07-04 | 2007-01-18 | Biotronik Vi Patent Ag | Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung |
US20070050009A1 (en) * | 2005-08-30 | 2007-03-01 | Aiden Flanagan | Bioabsorbable stent |
DE102005050344A1 (de) | 2005-10-20 | 2007-05-03 | Siemens Ag | Kryokatheter zur Einführung in ein Körpergefäß sowie medizinische Untersuchungs- und Behandlungsvorrichtung |
US20070135908A1 (en) * | 2005-12-08 | 2007-06-14 | Zhao Jonathon Z | Absorbable stent comprising coating for controlling degradation and maintaining pH neutrality |
DE102005059271B4 (de) * | 2005-12-12 | 2019-02-21 | Siemens Healthcare Gmbh | Kathetervorrichtung |
DE102005059261B4 (de) | 2005-12-12 | 2013-09-05 | Siemens Aktiengesellschaft | Kathetervorrichtung zur Behandlung eines teilweisen und/oder vollständigen Gefässverschlusses und Röntgeneinrichtung |
DE102005059262B4 (de) | 2005-12-12 | 2008-02-07 | Siemens Ag | Kathetervorrichtung |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
EP1806161B1 (de) * | 2006-01-10 | 2009-03-04 | Acrostak Corp. BVI | Implantat zur Behandlung der Innenwände eines Resektionshohlraumes |
US8089029B2 (en) * | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
DE102006011348B4 (de) * | 2006-03-11 | 2015-10-08 | Biotronik Vi Patent Ag | Verfahren zur Erzeugung einer in physiologischer Umgebung korrosionshemmenden Schicht auf einem Formkörper |
EP1835042A1 (de) * | 2006-03-18 | 2007-09-19 | Acrostak Corp. | Magnesium-Legierung mit verbesserter Kombination der mechanischen Eigenschaften und des Korrosionsverhaltens |
WO2007107286A2 (en) * | 2006-03-18 | 2007-09-27 | Acrostak Corp. Bvi | Magnesium-based alloy with improved combination of mechanical and corrosion characteristics |
DE102006015457A1 (de) * | 2006-03-31 | 2007-10-04 | Biotronik Vi Patent Ag | Magnesiumlegierung und dazugehöriges Herstellungsverfahren |
US20070239253A1 (en) * | 2006-04-06 | 2007-10-11 | Jagger Karl A | Oscillation assisted drug elution apparatus and method |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
KR20080113280A (ko) * | 2006-04-28 | 2008-12-29 | 바이오마그네슘 시스템즈 리미티드 | 생물분해성 마그네슘 합금 및 그 용도 |
US20070288085A1 (en) * | 2006-05-31 | 2007-12-13 | Furst Joseph G | Absorbable medical devices with specific design features |
US20070282432A1 (en) * | 2006-05-31 | 2007-12-06 | Stinson Jonathan S | Implantable medical endoprostheses |
US9265865B2 (en) * | 2006-06-30 | 2016-02-23 | Boston Scientific Scimed, Inc. | Stent having time-release indicator |
US20080015578A1 (en) * | 2006-07-12 | 2008-01-17 | Dave Erickson | Orthopedic implants comprising bioabsorbable metal |
CA2659761A1 (en) | 2006-08-02 | 2008-02-07 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
DE102006038241A1 (de) * | 2006-08-07 | 2008-02-14 | Biotronik Vi Patent Ag | Stent mit einer genisteinhaltigen Beschichtung oder Kavitätenfüllung |
DE102006038236A1 (de) * | 2006-08-07 | 2008-02-14 | Biotronik Vi Patent Ag | Biodegradierbarer Stent mit einer aktiven Beschichtung |
DE102006038231A1 (de) | 2006-08-07 | 2008-02-14 | Biotronik Vi Patent Ag | Implantat aus einem biokorrodierbaren metallischen Werkstoff mit einer Beschichtung aus einer Organosiliziumverbindung |
DE102006040936A1 (de) * | 2006-08-31 | 2008-03-13 | Siemens Ag | Katheter zum Entfernen von Gewebe aus einem Hohlorgan |
US7955382B2 (en) | 2006-09-15 | 2011-06-07 | Boston Scientific Scimed, Inc. | Endoprosthesis with adjustable surface features |
JP2010503488A (ja) * | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | 磁化された生体内分解性の内部人工器官 |
ATE517590T1 (de) | 2006-09-15 | 2011-08-15 | Boston Scient Ltd | Biologisch erodierbare endoprothesen |
JP2010503489A (ja) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | 生体内分解性内部人工器官およびその製造方法 |
EP2066363A2 (de) * | 2006-09-15 | 2009-06-10 | Boston Scientific Limited | Endoprothese mit magnetischen induktionspartikeln |
EP2959925B1 (de) | 2006-09-15 | 2018-08-29 | Boston Scientific Limited | Medizinische vorrichtungen und verfahren zu ihrer herstellung |
CA2663304A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Bioerodible endoprosthesis with biostable inorganic layers |
CA2663762A1 (en) | 2006-09-18 | 2008-03-27 | Boston Scientific Limited | Endoprostheses |
CN102512711A (zh) * | 2006-09-22 | 2012-06-27 | 友和安股份公司 | 由生物可降解金属构成的植入物及其制造方法 |
FR2906454B1 (fr) * | 2006-09-28 | 2009-04-10 | Perouse Soc Par Actions Simpli | Implant destine a etre place dans un conduit de circulation du sang. |
EP2204196A4 (de) | 2006-11-17 | 2012-11-07 | Nat Inst For Materials Science | Medizinische vorrichtung auf magnesiumbasis und herstellungsverfahren dafür |
US7651527B2 (en) * | 2006-12-15 | 2010-01-26 | Medtronic Vascular, Inc. | Bioresorbable stent |
DE102006060501A1 (de) | 2006-12-19 | 2008-06-26 | Biotronik Vi Patent Ag | Verfahren zur Herstellung einer korrosionshemmenden Beschichtung auf einem Implantat aus einer biokorrodierbaren Magnesiumlegierung sowie nach dem Verfahren hergestelltes Implantat |
US8080055B2 (en) | 2006-12-28 | 2011-12-20 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
MX2009007663A (es) | 2007-01-21 | 2009-10-13 | Hemoteq Ag | Dispositivo medico para el tratamiento de estenosis de pasajes corporales y para la prevencion de reestenosis inminente. |
DE102007034350A1 (de) | 2007-07-24 | 2009-01-29 | Hemoteq Ag | Biologisch abbaubare Gefäßstütze |
WO2008092435A2 (de) | 2007-01-30 | 2008-08-07 | Hemoteq Ag | Biologisch abbaubare gefässstütze |
DE102007008479A1 (de) * | 2007-02-21 | 2008-09-04 | Orlowski, Michael, Dr. | Beschichtetes Expandierbares System |
US20080243234A1 (en) * | 2007-03-27 | 2008-10-02 | Medtronic Vascular, Inc. | Magnesium Alloy Stent |
US20080249608A1 (en) * | 2007-04-04 | 2008-10-09 | Vipul Dave | Bioabsorbable Polymer, Bioabsorbable Composite Stents |
CA2687637A1 (en) * | 2007-05-22 | 2008-11-27 | Cinvention Ag | Partially degradable scaffolds for biomedical applications |
DE102007030438A1 (de) | 2007-06-29 | 2009-01-08 | Biotronik Vi Patent Ag | Implantat aus einer biokorrodierbaren Magnesiumlegierung und mit einer Beschichtung aus einem Poly(orthoester) |
US9192697B2 (en) | 2007-07-03 | 2015-11-24 | Hemoteq Ag | Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis |
DE102007038799A1 (de) | 2007-08-17 | 2009-02-19 | Biotronik Vi Patent Ag | Implantat aus einer biokorrodierbaren Magnesiumlegierung und mit einer Beschichtung aus einem biokorrodierbaren Polyphosphazen |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
US8118857B2 (en) | 2007-11-29 | 2012-02-21 | Boston Scientific Corporation | Medical articles that stimulate endothelial cell migration |
DE102007061647A1 (de) | 2007-12-20 | 2009-07-02 | Biotronik Vi Patent Ag | Implantat mit einem Grundkörper aus einer biokorrodierbaren Legierung |
US8801778B2 (en) | 2007-12-20 | 2014-08-12 | Biotronik Vi Patent Ag | Implant with a base body of a biocorrodible alloy |
DE102008006455A1 (de) | 2008-01-29 | 2009-07-30 | Biotronik Vi Patent Ag | Implantat mit einem Grundkörper aus einer biokorrodierbaren Legierung und einer korrosionshemmenden Beschichtung |
DE102008006654A1 (de) | 2008-01-30 | 2009-08-06 | Biotronik Vi Patent Ag | Implantat mit einem Grundkörper aus einer biokorrodierbaren Legierung |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
DE102008002471A1 (de) | 2008-06-17 | 2009-12-24 | Biotronik Vi Patent Ag | Stent mit einer Beschichtung oder einem Grundkörper, der ein Lithiumsalz enthält, und Verwendung von Lithiumsalzen zur Restenoseprophylaxe |
DE102008040573A1 (de) | 2008-07-21 | 2010-01-28 | Biotronik Vi Patent Ag | Aptamer beschichtetes Implantat, Herstellverfahren und Verwendungen |
DE102008040572A1 (de) | 2008-07-21 | 2010-01-28 | Biotronik Vi Patent Ag | Implantat mit Beschichtung |
DE102008040786A1 (de) | 2008-07-28 | 2010-02-04 | Biotronik Vi Patent Ag | Biokorrodierbares Implantat mit einer Beschichtung enthaltend eine wirkstofftragende Polymermatrix |
DE102008040787A1 (de) | 2008-07-28 | 2010-02-04 | Biotronik Vi Patent Ag | Biokorrodierbares Implantat mit einer Beschichtung enthaltend ein Hydrogel |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US9119906B2 (en) | 2008-09-24 | 2015-09-01 | Integran Technologies, Inc. | In-vivo biodegradable medical implant |
DE102008042576A1 (de) | 2008-10-02 | 2010-04-08 | Biotronik Vi Patent Ag | Biokorrodierbare Magnesiumlegierung |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
DE102008043277A1 (de) * | 2008-10-29 | 2010-05-06 | Biotronik Vi Patent Ag | Implantat aus einer biokorrodierbaren Eisen- oder Magnesiumlegierung |
DE102008043736A1 (de) | 2008-11-14 | 2010-05-20 | Biotronik Vi Patent Ag | Biokorrodierbares Implantat mit einer Wirkstoff-enthaltenden Beschichtung |
DE102008043970A1 (de) | 2008-11-21 | 2010-05-27 | Biotronik Vi Patent Ag | Verfahren zur Herstellung einer korrosionshemmenden Beschichtung auf einem Implantat aus einer biokorrodierbaren Magnesiumlegierung sowie nach dem Verfahren hergestelltes Implantat |
DE102008044221A1 (de) | 2008-12-01 | 2010-06-02 | Biotronik Vi Patent Ag | Stent mit einer Struktur aus einem biokorrodierbaren Werkstoff und einem gesteuerten Korrosionsverhalten |
EP2213314B1 (de) | 2009-01-30 | 2016-03-23 | Biotronik VI Patent AG | Implantat mit einem Grundkörper aus einer biokorrodierbaren Magnesiumlegierung |
WO2010101901A2 (en) | 2009-03-02 | 2010-09-10 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
DE102009002153A1 (de) | 2009-04-02 | 2010-10-21 | Biotronik Vi Patent Ag | Implantat aus einem biokorrodierbaren metallischen Werkstoff mit einer nanopartikel-haltigen Silanbeschichtung und dazugehöriges Herstellungsverfahren |
US8435281B2 (en) | 2009-04-10 | 2013-05-07 | Boston Scientific Scimed, Inc. | Bioerodible, implantable medical devices incorporating supersaturated magnesium alloys |
DE102009025511A1 (de) * | 2009-06-19 | 2010-12-23 | Qualimed Innovative Medizin-Produkte Gmbh | Implantat mit einem vom Körper resorbierbaren metallischen Werkstoff |
EP2266507B1 (de) | 2009-06-22 | 2015-07-29 | Biotronik VI Patent AG | Stent mit verbessertem Stentdesign |
EP2266508A1 (de) | 2009-06-25 | 2010-12-29 | Biotronik VI Patent AG | Stent mit verbessertem Stentdesign |
EP2266638A3 (de) * | 2009-06-25 | 2014-08-13 | Biotronik VI Patent AG | Biokorrodierbares Implantat mit einer aktiven Beschichtung |
JP2012532670A (ja) | 2009-07-10 | 2012-12-20 | ボストン サイエンティフィック サイムド,インコーポレイテッド | 薬剤搬送バルーンのためのナノ結晶の使用 |
WO2011008393A2 (en) * | 2009-07-17 | 2011-01-20 | Boston Scientific Scimed, Inc. | Nucleation of drug delivery balloons to provide improved crystal size and density |
US20110034990A1 (en) | 2009-08-06 | 2011-02-10 | Alexander Borck | Biocorrodible implant with active coating |
EP2289575B1 (de) | 2009-08-06 | 2017-07-05 | Biotronik VI Patent AG | Medizinisches Implantat enthaltend eine antioxidative Substanz |
JP5830467B2 (ja) | 2009-10-30 | 2015-12-09 | アクロシュターク コープ ビーヴイアイ,トルトーラAcrostak Corp BVI, Tortola | 超純マグネシウムベースの材料から形成される生分解性の埋め込み型医療用デバイス |
US20110160645A1 (en) * | 2009-12-31 | 2011-06-30 | Boston Scientific Scimed, Inc. | Cryo Activated Drug Delivery and Cutting Balloons |
WO2011119573A1 (en) | 2010-03-23 | 2011-09-29 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
CA2793568C (en) | 2010-03-25 | 2015-12-29 | Biotronik Ag | Implant made of a biodegradable magnesium alloy |
EP2371404A3 (de) | 2010-03-30 | 2014-08-20 | Biotronik AG | Medizinisches Implantat mit einer Beschichtung bestehend aus oder enthaltend mindestens einen Nitro-Statin-Wirkstoff |
DE102010018541A1 (de) * | 2010-04-28 | 2011-11-03 | Acandis Gmbh & Co. Kg | Verfahren zur Herstellung einer medizinischen Vorrichtung |
US9072618B2 (en) | 2010-05-06 | 2015-07-07 | Biotronik Ag | Biocorrodable implant in which corrosion may be triggered or accelerated after implantation by means of an external stimulus |
EP2582408B1 (de) | 2010-06-21 | 2014-09-10 | Zorion Medical, Inc. | Bioresorbierbare implantate |
EP2585125B1 (de) | 2010-06-25 | 2014-11-19 | Fort Wayne Metals Research Products Corporation | Biologisch abbaubarer verbunddraht für medizinische vorrichtungen |
WO2012030668A1 (en) | 2010-08-30 | 2012-03-08 | SinuSys Corporation | Device and kit for inserting a sinus dilator |
US8889211B2 (en) | 2010-09-02 | 2014-11-18 | Boston Scientific Scimed, Inc. | Coating process for drug delivery balloons using heat-induced rewrap memory |
EP2438891A1 (de) | 2010-10-08 | 2012-04-11 | Biotronik AG | Stent mit erhöhter Sichtbarkeit im Röntgenbild |
EP2446863A1 (de) | 2010-10-29 | 2012-05-02 | Biotronik AG | Stent mit radial asymmetrischer Kraftverteilung |
US8961592B2 (en) | 2010-11-12 | 2015-02-24 | Biotronik Ag | Functionalized RGD peptidomimetics and their manufacture, and implant having a coating containing such functional-ized RGD peptidomimetics |
DE102010043814A1 (de) | 2010-11-12 | 2012-05-16 | Biotronik Ag | Funktionalisierte RGD-Peptidmimetika und deren Herstellung sowie Implantat mit einer Beschichtung, die solche funktionalisierte RGD-Peptidmimetika enthält |
EP2452702B1 (de) | 2010-11-12 | 2015-03-04 | Biotronik AG | Funktionalisierte RGD-Peptidmimetika und deren Herstellung sowie Implantat mit einer Beschichtung, die solche funktionalisierte RGD-Peptidmimetika enthält |
US8986369B2 (en) | 2010-12-01 | 2015-03-24 | Zorion Medical, Inc. | Magnesium-based absorbable implants |
US20120158123A1 (en) | 2010-12-15 | 2012-06-21 | Biotronik Ag | Polymer stent |
TWI548427B (zh) | 2010-12-21 | 2016-09-11 | 星瑟斯有限公司 | 含有生物可降解鎂系合金之醫療植入物及其製造方法 |
DE202011001927U1 (de) | 2011-01-25 | 2011-04-07 | Sellin, Lothar | Naturstent |
US8669360B2 (en) | 2011-08-05 | 2014-03-11 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
US9522219B2 (en) | 2011-08-15 | 2016-12-20 | Hemoteq Ag | Resorbable stents which contain a magnesium alloy |
US9056152B2 (en) | 2011-08-25 | 2015-06-16 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
EP2630978B1 (de) * | 2012-02-22 | 2018-10-31 | Biotronik AG | Implantat und verfahren zur herstellung desselben |
CA2862297A1 (en) | 2012-02-29 | 2013-09-06 | SinuSys Corporation | Devices and methods for dilating a paranasal sinus opening and for treating sinusitis |
US10246763B2 (en) | 2012-08-24 | 2019-04-02 | The Regents Of The University Of California | Magnesium-zinc-strontium alloys for medical implants and devices |
US9504554B2 (en) | 2013-01-16 | 2016-11-29 | Biotronik Ag | Microstructured absorbable implant |
US9687263B2 (en) | 2013-05-30 | 2017-06-27 | SinuSys Corporation | Devices and methods for inserting a sinus dilator |
EP2992925B1 (de) | 2014-09-04 | 2022-09-07 | BIOTRONIK SE & Co. KG | Intravaskuläre elektrodenleitung und intravaskuläre stimulationsvorrichtung damit |
JP6089053B2 (ja) * | 2015-03-16 | 2017-03-01 | 有限会社エスク | 防食能を有する生分解性金属表面修飾ステント |
DE102016007176A1 (de) | 2015-06-11 | 2017-01-12 | Meotec GmbH & Co. KG | Resorbierbares Implantat mit hoher Reinheit und guten mechanischen Eigenschaften |
KR102170607B1 (ko) | 2015-08-20 | 2020-10-27 | 후지 라이트 메탈 가부시키가이샤 | 생체에 사용 가능한 합금제 부재 및 그의 제조 방법 |
EP3342433A1 (de) | 2016-12-27 | 2018-07-04 | MeKo Laserstrahl-Materialbearbeitungen e.K. | Stent aus einer biologisch abbaubaren magnesiumlegierung mit einer magnesiumfluorid-beschichtung und einer organischen beschichtung |
DE202018001853U1 (de) | 2018-04-12 | 2018-06-14 | Lothar Sellin | Bioresorbierbares Implantat |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4610241A (en) * | 1984-07-03 | 1986-09-09 | Gordon Robert T | Atherosclerosis treatment method |
EP0518061A2 (de) * | 1991-05-23 | 1992-12-16 | REHAU AG + Co | Medizinische Arbeitsmittel |
EP0770391A2 (de) * | 1995-10-26 | 1997-05-02 | L'oreal | Verwendung von Lanthanide-, Zinn-, Mangan-, Yttrium-, Kobalt-, Barium-, Strontiumsalzen in pharmazeutische Zubereitungen |
US6478815B1 (en) * | 2000-09-18 | 2002-11-12 | Inflow Dynamics Inc. | Vascular and endoluminal stents |
WO2002100452A1 (de) * | 2001-06-11 | 2002-12-19 | Medizinische Hochschule Hannover | Medizinisches implantat für den menschlichen oder tierischen körper |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2219056A (en) * | 1938-11-30 | 1940-10-22 | Magnesium Dev Corp | Magnesium base alloy |
FR1412298A (fr) * | 1963-10-26 | 1965-09-24 | Fuchs Otto | Procédé pour améliorer les propriétés mécaniques et la résistance à l'oxydation d'alliages de magnésium renfermant du zirconium et alliages fabriqués suivant ce procédé |
GB1237035A (en) * | 1969-08-20 | 1971-06-30 | Tsi Travmatologii I Ortopedii | Magnesium-base alloy for use in bone surgery |
AU544762B2 (en) | 1981-03-25 | 1985-06-13 | Luxfer Group Limited | Magnesium base rare earth alloy |
AU3708495A (en) * | 1994-08-01 | 1996-03-04 | Franz Hehmann | Selected processing for non-equilibrium light alloys and products |
US6102904A (en) * | 1995-07-10 | 2000-08-15 | Interventional Technologies, Inc. | Device for injecting fluid into a wall of a blood vessel |
US5807404A (en) * | 1996-09-19 | 1998-09-15 | Medinol Ltd. | Stent with variable features to optimize support and method of making such stent |
DE19731021A1 (de) * | 1997-07-18 | 1999-01-21 | Meyer Joerg | In vivo abbaubares metallisches Implantat |
US6206916B1 (en) * | 1998-04-15 | 2001-03-27 | Joseph G. Furst | Coated intraluminal graft |
EP0966979B1 (de) * | 1998-06-25 | 2006-03-08 | Biotronik AG | Implantierbare, bioresorbierbare Gefässwandstütze, insbesondere Koronarstent |
US6264595B1 (en) * | 1999-02-04 | 2001-07-24 | Mobeta, Inc. | Radioactive transition metal stents |
EP1175236A1 (de) * | 1999-04-23 | 2002-01-30 | Agion Technologies, L.L.C. | Stent mit antimikrobiellem mittel |
US8888688B2 (en) * | 2000-04-03 | 2014-11-18 | Intuitive Surgical Operations, Inc. | Connector device for a controllable instrument |
US6716444B1 (en) * | 2000-09-28 | 2004-04-06 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US6979347B1 (en) * | 2000-10-23 | 2005-12-27 | Advanced Cardiovascular Systems, Inc. | Implantable drug delivery prosthesis |
CA2438237A1 (en) * | 2001-02-23 | 2002-08-29 | Angiogene Inc. | Use of occlusion device for the local delivery of biologically active dna therapeutic compounds for treating aneurysms and use thereof |
DE10118603A1 (de) * | 2001-04-12 | 2002-10-17 | Gerd Hausdorf | Biologisch abbaubare medizinische Implantate aus der Kombination von metallischen und nichtmetallischen Werkstoffen |
DE10163106A1 (de) * | 2001-12-24 | 2003-07-10 | Univ Hannover | Medizinische Implantate, Prothesen, Protheseteile, medizinische Instrumente, Geräte und Hilfsmittel aus einem halogenid-modifizierten Magnesiumwerkstoff |
IL147561A (en) * | 2002-01-10 | 2005-03-20 | Dead Sea Magnesium Ltd | High temperature resistant magnesium alloys |
DE10207161B4 (de) * | 2002-02-20 | 2004-12-30 | Universität Hannover | Verfahren zur Herstellung von Implantaten |
CN1655738A (zh) * | 2002-05-20 | 2005-08-17 | 奥勃斯医学技术股份有限公司 | 可植入的药物洗脱医疗装置 |
DE10253634A1 (de) * | 2002-11-13 | 2004-05-27 | Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin | Endoprothese |
DE10361942A1 (de) * | 2003-12-24 | 2005-07-21 | Restate Patent Ag | Radioopaker Marker für medizinische Implantate |
DE102004026104A1 (de) * | 2004-05-25 | 2005-12-15 | Restate Patent Ag | Implantat zur Gefäßligatur |
DE102004043231A1 (de) * | 2004-09-07 | 2006-03-09 | Biotronik Vi Patent Ag | Endoprothese aus einer Magnesiumlegierung |
DE102004043232A1 (de) * | 2004-09-07 | 2006-03-09 | Biotronik Vi Patent Ag | Endoprothese aus einer Magnesiumlegierung |
DE102005003188A1 (de) * | 2005-01-20 | 2006-07-27 | Restate Patent Ag | Medizinisches Implantat aus einer amorphen oder nanokristallinen Legierung |
JP2008536005A (ja) * | 2005-03-08 | 2008-09-04 | ペ,ドン−ヒョン | ミッシュメタルが添加されたマグネシウム合金、ミッシュメタルが添加されたマグネシウム合金加工材の製造方法及びこれによって製造されるマグネシウム合金加工材 |
US7869858B2 (en) * | 2005-05-12 | 2011-01-11 | General Electric Company | Patient table system and apparatus |
WO2006125278A1 (en) * | 2005-05-26 | 2006-11-30 | Cast Centre Pty Ltd | Hpdc magnesium alloy |
DE102006015457A1 (de) * | 2006-03-31 | 2007-10-04 | Biotronik Vi Patent Ag | Magnesiumlegierung und dazugehöriges Herstellungsverfahren |
DE102006038237A1 (de) * | 2006-08-07 | 2008-02-14 | Biotronik Vi Patent Ag | Markerlegierung |
IL177568A (en) * | 2006-08-17 | 2011-02-28 | Dead Sea Magnesium Ltd | Creep resistant magnesium alloy with improved ductility and fracture toughness for gravity casting applications |
JP2010516403A (ja) * | 2007-01-26 | 2010-05-20 | ボストン サイエンティフィック リミテッド | 植込み型医療用内部人工器官 |
WO2008098922A2 (en) * | 2007-02-13 | 2008-08-21 | Cinvention Ag | Biodegradable porous stent |
-
2002
- 2002-11-13 DE DE10253634A patent/DE10253634A1/de not_active Withdrawn
-
2003
- 2003-10-11 US US10/535,084 patent/US20060246107A1/en not_active Abandoned
- 2003-10-17 DE DE50302281T patent/DE50302281D1/de not_active Expired - Lifetime
- 2003-10-17 EP EP03090354A patent/EP1419793B1/de not_active Expired - Lifetime
- 2003-10-17 AT AT03090354T patent/ATE316390T1/de not_active IP Right Cessation
- 2003-11-10 AT AT03779881T patent/ATE388696T1/de not_active IP Right Cessation
- 2003-11-10 DE DE50309382T patent/DE50309382D1/de not_active Expired - Lifetime
- 2003-11-10 EP EP03779881A patent/EP1562565B1/de not_active Expired - Lifetime
- 2003-11-10 AU AU2003288029A patent/AU2003288029A1/en not_active Abandoned
- 2003-11-10 WO PCT/EP2003/012532 patent/WO2004043474A2/de active IP Right Grant
- 2003-11-11 US US10/706,717 patent/US8425835B2/en active Active
- 2003-11-13 JP JP2003383386A patent/JP5073913B2/ja not_active Expired - Lifetime
-
2009
- 2009-10-08 US US12/575,613 patent/US20100119576A1/en not_active Abandoned
- 2009-10-08 US US12/575,596 patent/US20100034899A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4610241A (en) * | 1984-07-03 | 1986-09-09 | Gordon Robert T | Atherosclerosis treatment method |
EP0518061A2 (de) * | 1991-05-23 | 1992-12-16 | REHAU AG + Co | Medizinische Arbeitsmittel |
EP0770391A2 (de) * | 1995-10-26 | 1997-05-02 | L'oreal | Verwendung von Lanthanide-, Zinn-, Mangan-, Yttrium-, Kobalt-, Barium-, Strontiumsalzen in pharmazeutische Zubereitungen |
US6478815B1 (en) * | 2000-09-18 | 2002-11-12 | Inflow Dynamics Inc. | Vascular and endoluminal stents |
WO2002100452A1 (de) * | 2001-06-11 | 2002-12-19 | Medizinische Hochschule Hannover | Medizinisches implantat für den menschlichen oder tierischen körper |
Non-Patent Citations (1)
Title |
---|
BERND HEUBLEIN, ROLAND ROHDE, MATHIAS NIEMEYER, VOLKER KASSE ET AL.: "Degradation of Metallic Alloys - A new Principle in Stent Technology?" ABSTRACTS-ACCIS 2000, Februar 2000 (2000-02), Seiten 14A-15A, XP002291050 02-2000 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10361941A1 (de) * | 2003-12-24 | 2005-07-28 | Restate Patent Ag | Magnesiumhaltige Beschichtung |
US8871829B2 (en) | 2003-12-24 | 2014-10-28 | Biotronik Vi Patent Ag | Radio-opaque marker for medical implants |
WO2005065737A1 (de) * | 2003-12-24 | 2005-07-21 | Biotronik Vi Patent Ag | Radioopaker marker für medizinische implantate |
DE102004043232A1 (de) * | 2004-09-07 | 2006-03-09 | Biotronik Vi Patent Ag | Endoprothese aus einer Magnesiumlegierung |
DE102004043231A1 (de) * | 2004-09-07 | 2006-03-09 | Biotronik Vi Patent Ag | Endoprothese aus einer Magnesiumlegierung |
US8840736B2 (en) | 2004-09-07 | 2014-09-23 | Biotronik Vi Patent Ag | Endoprosthesis comprising a magnesium alloy |
US9468704B2 (en) | 2004-09-07 | 2016-10-18 | Biotronik Vi Patent Ag | Implant made of a biodegradable magnesium alloy |
EP1642551A1 (de) * | 2004-09-09 | 2006-04-05 | Biotronik VI Patent AG | Implantat mit geringer Radialfestigkeit |
US9700652B2 (en) | 2005-01-20 | 2017-07-11 | Biotronik Vi Patent Ag | Absorbable medical implant made of fiber-reinforced magnesium or fiber-reinforced magnesium alloys |
DE102005003188A1 (de) * | 2005-01-20 | 2006-07-27 | Restate Patent Ag | Medizinisches Implantat aus einer amorphen oder nanokristallinen Legierung |
WO2007035791A3 (en) * | 2005-09-19 | 2007-05-10 | Cook Inc | Graft with bioabsorbable support frame |
US8663308B2 (en) | 2005-09-19 | 2014-03-04 | Cook Medical Technologies Llc | Graft with bioabsorbable support frame |
US7939146B2 (en) | 2006-08-07 | 2011-05-10 | Biotronik Vi Patent Ag | Marker composite for medical implants |
DE102006038233A1 (de) * | 2006-08-07 | 2008-02-14 | Biotronik Vi Patent Ag | Markerkomposit für medizinische Implantate |
EP2000551A1 (de) | 2007-05-28 | 2008-12-10 | Acrostak Corp. BVI | Magnesiumbasierte Legierungen |
US8202477B2 (en) | 2007-05-28 | 2012-06-19 | Acrostak Corp. Bvi | Magnesium-based alloy |
US10016530B2 (en) | 2008-09-30 | 2018-07-10 | Biotronik Ag | Implant made of a biodegradable magnesium alloy |
WO2014048585A1 (de) | 2012-09-25 | 2014-04-03 | Mdi Dental- Und Implantattechnik Gmbh | Pharmazeutische beschichtung für aufbauten von zahnimplantaten |
DE102012018816A1 (de) | 2012-09-25 | 2014-03-27 | Mdi Dental- Und Implantattechnik Gmbh | Pharmazeutische Beschichtung für Aufbauten von Zahnimplantaten |
Also Published As
Publication number | Publication date |
---|---|
EP1562565A2 (de) | 2005-08-17 |
WO2004043474A3 (de) | 2005-01-13 |
AU2003288029A8 (en) | 2004-06-03 |
US20040098108A1 (en) | 2004-05-20 |
AU2003288029A1 (en) | 2004-06-03 |
ATE316390T1 (de) | 2006-02-15 |
US20100034899A1 (en) | 2010-02-11 |
JP2004160236A (ja) | 2004-06-10 |
DE50302281D1 (de) | 2006-04-13 |
US20060246107A1 (en) | 2006-11-02 |
ATE388696T1 (de) | 2008-03-15 |
DE50309382D1 (de) | 2008-04-24 |
EP1562565B1 (de) | 2008-03-12 |
EP1419793B1 (de) | 2006-01-25 |
JP5073913B2 (ja) | 2012-11-14 |
US8425835B2 (en) | 2013-04-23 |
DE10253634A1 (de) | 2004-05-27 |
US20100119576A1 (en) | 2010-05-13 |
EP1419793A1 (de) | 2004-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1562565B1 (de) | Verwendung eines oder mehrerer der elemente aus der gruppe yttrium, neodym und zirconium | |
DE60105554T3 (de) | Endovaskulärer Stent mit Tacrolimus enthaltender Beschichtung | |
EP1389471B1 (de) | Verfahren zur Herstellung eines implantationsfähigen Stents mit einer polymeren Beschichtung aus hochmolekularem Poly-L-Lactid | |
EP1603606B1 (de) | Endovaskuläres implantat mit einer zumindest abschnittsweisen aktiven beschichtung aus ratjadon und/oder einem ratjadon-derivat | |
EP2744532B1 (de) | Resorbierbare stents, welche eine magnesiumlegierung enthalten | |
DE60104396T2 (de) | Medizinische vorrichtung | |
EP1389472B1 (de) | Endovaskuläres Implantat mit aktiver Beschichtung | |
DE4334272C2 (de) | Beschichtung für Biomaterial und seine Verwendung | |
DE69935716T2 (de) | Stent mit glatten enden | |
DE60221287T4 (de) | Intraluminale vorrichtung mit einer ein therapeutisches-mittel enthaltenden beschichtung | |
EP1702592B1 (de) | System zur Behandlung ausgedehnter obliterierender Erkrankungen eines Gefässes | |
DE10361941A1 (de) | Magnesiumhaltige Beschichtung | |
DE19754870A1 (de) | Gefäßprothese | |
DE102007059755A1 (de) | Implantate mit membrandiffusionskontrollierter Wirkstofffreisetzung | |
DE60004630T2 (de) | Arzneimittel und verfahren zur verabreichung von wasserunlöslichen paclitaxelderivaten | |
EP2138130A1 (de) | Beschichteter Stent mit axial variierender Elutionscharakteristik | |
EP0652017B2 (de) | Beschichtung für Biomaterial | |
DE60207265T2 (de) | Heparin-stent | |
EP2415489B1 (de) | Polylactid-beschichtetes Implantat aus einer biokorrodierbaren Magnesiumlegierung | |
EP2540293A1 (de) | Erhöhung der effizienz der therapeutischen Wirkung pharmakologischer Wirsktoff-freissetzender medizinischer Vorrichtungen | |
EP2701757B1 (de) | Implantierbare gefässstütze | |
EP2462962B1 (de) | Implantat mit einer das implantat zumindest bereichsweise bedeckenden, wirkstoffhaltigen beschichtung | |
EP2500043A1 (de) | Medizinprodukt mit einer aktiven Beschichtung | |
DE102008040572A1 (de) | Implantat mit Beschichtung | |
EP3032949A1 (de) | Mittel enthaltend mikropartikel zur reinigung und zum schutz von technischen oberflächen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003779881 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003779881 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006246107 Country of ref document: US Ref document number: 10535084 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10535084 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003779881 Country of ref document: EP |